Dr. Petrylak of Yale University on Dr. Katz show on WABC Radio today on Provenge

Quote

Anonymous

Guest
WABC - Petrylak interview

.... excellent interview w/ Dr. Dan Petrylak:

Dr. Katz show- Sunday, Novemberr 25, 2012


Dr. Daniel Petrylak, Internationally known Meical Oncologist and Head of the Genitourinary Cancer Program at the Yale Cancer Center and the Smilow Cancer Hospital, discusses the newest agents of prostate cancer, specifically Provenge, which is the immune therapy for prostate cancer. Dr Petrylak has treated over 200 patients with Provenge:

http://wabcradio.com/Article.asp?id=2580374&spid=32933

Great Stuff !!!!!
 












Provenge in earlier stage disease will quadruple the available patient population for Provenge. According to Dr. Petrylak, Provenge use in earlier stage disease is medically logical and should happen.

You obviously do not care about prostate cancer patients or Provenge sales growth. You obviously do not work for the company.
 






Anonymous said:
WABC - Petrylak interview

.... excellent interview w/ Dr. Dan Petrylak:

Dr. Katz show- Sunday, Novemberr 25, 2012


Dr. Daniel Petrylak, Internationally known Meical Oncologist and Head of the Genitourinary Cancer Program at the Yale Cancer Center and the Smilow Cancer Hospital, discusses the newest agents of prostate cancer, specifically Provenge, which is the immune therapy for prostate cancer. Dr Petrylak has treated over 200 patients with Provenge:

http://wabcradio.com/Article.asp?id=2580374&spid=32933

Great Stuff !!!!!
Click to expand...

Any insight as to why sales are falling so rapidly at University Centers? That's been at the heart of the declining sales for the last quarters. Have most decided on better treatment plans that don't include Provenge? Did urologists stop referrring and are doing it locally? Frankly, this has been the bewildering issue for the last two quarters.
 






Thanks for the link for the radio interview. Dr. Petrylak is an important KOL for Provenge. He has been treating patients with Provenge for a decade. He was involved in the earlier clinical trials. To date he has treated over 200 patients with Provenge. It is good to see he is advocating earlier use of Provenge. Interesting that the most internationally acclaimed and smartest MDs are the biggest supporters of Provenge.
 












Anonymous said:
Any insight as to why sales are falling so rapidly at University Centers? That's been at the heart of the declining sales for the last quarters. Have most decided on better treatment plans that don't include Provenge? Did urologists stop referrring and are doing it locally? Frankly, this has been the bewildering issue for the last two quarters.
Click to expand...

There has been a shift in some areas from the Univ/Academic centers to the community oncs and uros. This happens with products that are more complex and a Univ center is more comfortable with from trials, etc. Gradually the community becomes more comfortable and begins to keep that patient and treat themselves. It is really a shift in the biz in territories and less a drop in total infusions.
 






Anonymous said:
There has been a shift in some areas from the Univ/Academic centers to the community oncs and uros. This happens with products that are more complex and a Univ center is more comfortable with from trials, etc. Gradually the community becomes more comfortable and begins to keep that patient and treat themselves. It is really a shift in the biz in territories and less a drop in total infusions.
Click to expand...


But, it is a drop in total infusions. So, if what you claim is true, business is shifting from Univ centers to local clinics AND business is being lost at the same time.

So, the growth in local clinics wouldn't be an indicator of future growth.

I'm not saying that's true, but it's a consequence of what you claim.

The alternative is that they are independent. Local clinics are growing and will continue to.
Then, the question is still WTF is going on with University centers?
 






Great to hear that Provenge will move to much earlier disease state. This is a tremendously large market. Provenge will do very well in this market because of its low side effects. Thanks for sharing the Dr. Petrylak interview. It is only a matter of time until Provenge achieves great success.
 












Top Bottom
Back
Quote